In Europe, less than 50% of patients on antihypertensive treatment is able to reduce their blood pressure levels below 140/90 mmHg and it is estimated that more than half of untreated hypertensives. 3.4 "To meet this challenge, the European Society of Hypertension (ESH by the acronym) has set a target that 70% of hypertensive patients achieve control of their blood pressure levels by 2015", said Professor Josep Redon, President of the ESH, adding: "Some European countries, such as Italy and France, have already committed to this initiative and soon we will meet with hypertension companies from other European countries to ensure support for the time to realize this common goal. "

To help physicians and patients achieve blood pressure targets and, thus, reduce the risk of developing serious cardiovascular events, Daiichi Sankyo continues to investigate the benefits of fixed-dose combination of olmesartan and amlodipine and developing solutions that involving health professionals and patients as part of their initiative HypertensionCare.

In this sense, soon will present new clinical data from phase 4 Sevitension study, comparing fixed-dose combination of olmesartan and amlodipine versus perindopril and amlodipine in reducing central blood pressure aórtica.5

It is estimated that between 80 and 85% of hypertensive patients may achieve blood pressure control with combinations of several fármacos.6 fixed dose combinations, which are the preferred treatment option according to the European Guidelines for management clinical simplify antihypertensive treatment, improve patient adherence and outcomes clínicos.6

Optimizing the management of hypertension will also be the focus of the satellite symposium "Ten years of olmesartan" that Daiichi Sankyo and Menarini organized within the next 23 th Congress of the European Society of Hypertension (ESH by the acronym) and will take place Milan (Italy) on June 14 from 15.00 to 17.00 hours.


 "In addition to our ongoing research on olmesartan-based antihypertensive therapies, we are very proud of our program HypertensionCare that helps doctors and patients to more effectively control the blood pressure levels," says Joris Versteden, Senior Medical Director at Daiichi Sankyo Europe.

As part of this initiative, last year launched the interactive portal hypertensive patient support, available in English for all of Europe (excluding the UK). Since then, the site has evolved and contains three distinct platforms: the original site dedicated to providing tools for healthcare professionals, one with hypertensive patient information and their families and a third that specifically promotes adherence of patients.

Adherence to treatment is a challenge for hypertensive patients. It is estimated that approximately 50% of patients discontinue treatment after a year.7 and lack of adherence has been identified as a major cause of failure to achieve blood pressure goals propuestas.8 support program myHypertensionCare patient aims to improve the understanding, commitment and compliance with treatment, accompanied by changes in lifestyle, all resulting in an improvement of the results clínicos.8, 9

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to research and innovative drug delivery in both mature and emerging markets, with the goal of addressing unmet medical diverse decks. The company was formed in 2005 through the merger of two Japanese companies with a long tradition, Daiichi and Sankyo. With net sales of close to 8,500 million euros, Daiichi Sankyo is one of the top 20 pharmaceutical companies in the world. In addition to a consolidated portfolio of drugs against hypertension, hyperlipidemia, and bacterial infections, Daiichi Sankyo seeks new therapies in cardiovascular and oncology. The Daiichi Sankyo Group has established the "Hybrid Business Model" that combines innovative and generic drugs in order to reach as many patients as possible.

The company's global headquarters is located in Tokyo. The Daiichi Sankyo's European headquarters is located in Munich and has subsidiaries in 12 European countries in addition to a global manufacturing facility located in Pfaffenhofen (Germany).

For more information, please visit or


Roberto Sánchez Martín. Corporate Communications Manager

Tel +34 91 5399911 roberto.sanchez @

Forward-Looking Statements

This press release contains forward-looking statements and information on the future development of the sector and on the legal and business conditions of Daiichi Sankyo Spain, SA Such statements are not final and are subject to change at any time, especially the common changes faced by a global pharmaceutical company, including the impact of the price of products and raw materials, medication safety, changes in exchange rates, regulations government, labor relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All statements included in this release are certain at the time of publication. Not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements expressed or implied in these statements. Daiichi Sankyo Spain, SA not assume any responsibility for updating these statements about the future development of the sector or the legal or business of the company.


1.      OMS. World Hypertension Day Brochure, 2013.

2.      Lawes, CM, Vander Hoorn, S. & Rodgers, A. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371 (9623):1513-8

3.      Wang YR, Alexander GC, Stafford RS, Outpatient Hypertension Treatment. Treatment Intensification, and Control in Western Europe and the United States. Arch Intern Med. 2007;167(2):141-147

4.      Wolf-Maier K et al. Hypertension Treatment and control in five European countries, Canada, and the United States.

5.      Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure. Accessed May 2013.

6.      Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension 2009, 27:000–000

7.      Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008; 336:1114–1117.

8.      World Health Organization Report 2003: Adherence to Long-Term Therapies. Accessed May 2013.

9.      Corrao G, Parodi A, Nicotra F, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29(3): 610–618.

10.    Scott, L. J. and McCormack, P. L. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 2008; 68(9): 1239-1272.

11.    Fabia et al., Antihypertensive activity of angiotensin II AT 1 receptor antagonists: a systematic review of studies with 24h ambulatory blood pressure monitoring. Journal of Hypertension 2007; 25(7): 1327-1336.

12.  Stumpe, K. O. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. Clin Ther 2004; 26 (Suppl A)A33-7


Photo By hugovillarroelabrego [Public domain or Public domain], via Wikimedia Commons